Lysogeny and bacteriophage host range within the Burkholderia cepacia complex

Journal of Medical Microbiology - Tập 52 Số 6 - Trang 483-490 - 2003
Ross Langley1, D. Kenna1, Peter Vandamme1, Rebecca Ure1, John R. W. Govan1
1Department of Medical Microbiology, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, UK 2Laboratorium voor Mikrobiologie, Faculteit Wetenschappen, Universiteit Gent, K. L. Ledeganckstraat 35, B-9000 Gent, Belgium#dReceived 11 October 2002 Accepted 12 February 2003

Tóm tắt

The Burkholderia cepacia complex comprises a group of nine closely related species that have emerged as life-threatening pulmonary pathogens in immunocompromised patients, particularly individuals with cystic fibrosis or chronic granulomatous disease. Attempts to explain the genomic plasticity, adaptability and virulence of the complex have paid little attention to bacteriophages, particularly the potential contribution of lysogenic conversion and transduction. In this study, lysogeny was observed in 10 of 20 representative strains of the B. cepacia complex. Three temperate phages and five lytic phages isolated from soils, river sediments or the plant rhizosphere were chosen for further study. Six phages exhibited T-even morphology and two were lambda-like. The host range of individual phages, when tested against 66 strains of the B. cepacia complex and a representative panel of other pseudomonads, was not species-specific within the B. cepacia complex and, in some phages, included Burkholderia gladioli and Pseudomonas aeruginosa. These new data indicate a potential role for phages of the B. cepacia complex in the evolution of these soil bacteria as pathogens of plants, humans and animals, and as novel therapeutic agents.

Từ khóa


Tài liệu tham khảo

Agodi, 2001, Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status, J Clin Microbiol, 39, 2891, 10.1128/JCM.39.8.2891-2896.2001

Allison, 2000, Serotype-converting bacteriophages and O-antigen modification in Shigella flexneri, Trends Microbiol, 8, 17, 10.1016/S0966-842X(99)01646-7

Aris, 2001, Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex.Survival linked to genomovar type, Am J Respir Crit Care Med, 164, 2102, 10.1164/ajrccm.164.11.2107022

Berriatua, 2001, Outbreak of subclinical mastitis in a flock of dairy sheep associated with Burkholderia cepacia complex infection, J Clin Microbiol, 39, 990, 10.1128/JCM.39.3.990-994.2001

Bevivino, 2002, Burkholderia cepacia complex bacteria from clinical and environmental sources in Italy: genomovar status and distribution of traits related to virulence and transmissibility, J Clin Microbiol, 40, 846, 10.1128/JCM.40.3.846-851.2002

Butler, 1995, Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard?, J Clin Microbiol, 33, 1001, 10.1128/JCM.33.4.1001-1004.1995

Cihlar, 1978, Characterization of bacteriophage CP1, an organic solvent sensitive phage associated with Pseudomonas cepacia, Can J Microbiol, 24, 1404, 10.1139/m78-224

Coenye, 2001, Taxonomy and identification of the Burkholderia cepacia complex, J Clin Microbiol, 39, 3427, 10.1128/JCM.39.10.3427-3436.2001

Environmental Protection, 2002, Burkholderia cepacia complex: proposed significant new use rule, Fed Regist, 67, 1179

Fisher, 1993, Source of Pseudomonas cepacia : ribotyping of isolates from patients and from the environment, J Pediatr, 123, 745, 10.1016/S0022-3476(05)80851-0

Govan, 1985, Typing of Pseudomonas cepacia by bacteriocin susceptibility and production, J Clin Microbiol, 22, 490, 10.1128/JCM.22.4.490-494.1985

Govan, 1998, Agricultural and medical microbiology: a time for bridging gaps, Microbiology, 144, 2373, 10.1099/00221287-144-9-2373

Govan, 1996, Burkholderia cepacia : medical, taxonomic and ecological issues, J Med Microbiol, 45, 395, 10.1099/00222615-45-6-395

Govan, 2000, Burkholderia cepacia – friend and foe, ASM News, 66, 124

Gutmann, 1990, A phasmid shuttle vector for the cloning of complex operons in Salmonella, Plasmid, 23, 42, 10.1016/0147-619X(90)90043-C

Hancock, 1997, Peptide antibiotics, Lancet, 349, 418, 10.1016/S0140-6736(97)80051-7

Holloway, 1960, Lysogeny in Pseudomonas aeruginosa, Aust J Exp Biol Med Sci, 38, 321, 10.1038/icb.1960.34

Holmes, 1998, Agricultural use of Burkholderia ( Pseudomonas ) cepacia : a threat to human health?, Emerg Infect Dis, 4, 221, 10.3201/eid0402.980209

Holmes, 1999, An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis, J Infect Dis, 179, 1197, 10.1086/314699

Hughes, 1997, Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia, Infect Immun, 65, 4281, 10.1128/IAI.65.10.4281-4287.1997

Jones, 2001, Burkholderia cepacia : current clinical issues, environmental controversies and ethical dilemmas, Eur Respir J, 17, 295, 10.1183/09031936.01.17202950

Kenna, 2003, Lack of correlation between O-serotype, bacteriophage susceptibility and genomovar status in the Burkholderia cepacia complex, FEMS Immunol Med Microbiol, 35, 87, 10.1016/S0928-8244(02)00442-X

Lessie, 1996, Genomic complexity and plasticity of Burkholderia cepacia, FEMS Microbiol Lett, 144, 117, 10.1111/j.1574-6968.1996.tb08517.x

Lewin, 1993, In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, cotrimoxazole, and ciprofloxacin against Pseudomonas cepacia, Antimicrob Agents Chemother, 37, 123, 10.1128/AAC.37.1.123

LiPuma, 1998, Burkholderia cepacia .Management issues and new insights, Clin Chest Med, 19, 473, 10.1016/S0272-5231(05)70094-0

LiPuma, 1999, Commercial use of Burkholderia cepacia, Emerg Infect Dis, 5, 305, 10.3201/eid0502.990226

LiPuma, 2000, Isolation of soil-borne genomovar III Burkholderia cepacia and lytic phages with interspecies host range, Pediatr Pulmonol, S20, 288

LiPuma, 2001, Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis, Am J Respir Crit Care Med, 164, 92, 10.1164/ajrccm.164.1.2011153

Mack, 1998, The detection of insertion sequences within the human pathogen Burkholderia pseudomallei which have been identified previously in Burkholderia cepacia, FEMS Microbiol Lett, 162, 69, 10.1111/j.1574-6968.1998.tb12980.x

Mahenthiralingam, 2000a, Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex, J Clin Microbiol, 38, 910, 10.1128/JCM.38.2.910-913.2000

Mahenthiralingam, 2000b, DNA-based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis , Burkholderia multivorans , Burkholderia stabilis , and Burkholderia cepacia genomovars I and III, J Clin Microbiol, 38, 3165, 10.1128/JCM.38.9.3165-3173.2000

Mahenthiralingam, 2002, Burkholderia cepacia complex infection in patients with cystic fibrosis, J Med Microbiol, 51, 533, 10.1099/0022-1317-51-7-533

Matsumoto, 1986, A generalized transducing phage of Pseudomonas cepacia, J Gen Microbiol, 132, 2583

Nzula, 2000, Sensitivity of the Burkholderia cepacia complex and Pseudomonas aeruginosa to transducing bacteriophages, FEMS Immunol Med Microbiol, 28, 307, 10.1111/j.1574-695X.2000.tb01491.x

Nzula, 2002, Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex, J Antimicrob Chemother, 50, 265, 10.1093/jac/dkf137

Parke, 2001, Diversity of the Burkholderia cepacia complex and implications for risk assessment of biological control strains, Annu Rev Phytopathol, 39, 225, 10.1146/annurev.phyto.39.1.225

Pirisi, 2000, Phage therapy – advantages over antibiotics?, Lancet, 356, 1418, 10.1016/S0140-6736(05)74059-9

Pitt, 1996, Type characterisation and antibiotic susceptibility of Burkholderia ( Pseudomonas ) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland, J Med Microbiol, 44, 203, 10.1099/00222615-44-3-203

Schuch, 2002, A bacteriolytic agent that detects and kills Bacillus anthracis, Nature, 418, 884, 10.1038/nature01026

Schulin, 2001, Chronic melioidosis in a patient with cystic fibrosis, J Clin Microbiol, 39, 1676, 10.1128/JCM.39.4.1676-1677.2001

Shaw, 1995, Biological activity of Burkholderia ( Pseudomonas ) cepacia lipopolysaccharide, FEMS Immunol Med Microbiol, 11, 99, 10.1111/j.1574-695X.1995.tb00095.x

Speert, 2002, Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada, Emerg Infect Dis, 8, 181, 10.3201/eid0802.010163

Sulakvelidze, 2001, Bacteriophage therapy, Antimicrob Agents Chemother, 45, 649, 10.1128/AAC.45.3.649-659.2001

Vandamme, 1997, Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp.nov, Int J Syst Bacteriol, 47, 1188, 10.1099/00207713-47-4-1188

Vandamme, 2003, Burkholderia cenocepacia sp.nov. – a new twist to an old story, Res Microbiol, 154, 91, 10.1016/S0923-2508(03)00026-3

Vermis, 2002, Evaluation of restriction fragment length polymorphism analysis of 16S rDNA as a tool for genomovar characterisation within the Burkholderia cepacia complex, FEMS Microbiol Lett, 214, 1, 10.1111/j.1574-6968.2002.tb11316.x

Visca, 2001, Travel-associated Burkholderia pseudomallei infection (melioidosis) in a patient with cystic fibrosis: a case report, Clin Infect Dis, 32, E15, 10.1086/317528

Weiss, 1994, Isolation and characterization of a generalized transducing phage for Xanthomonas campestris pv. campestris, J Bacteriol, 176, 3354, 10.1128/JB.176.11.3354-3359.1994

Wigley, 2000, Multiple chromosomes in Burkholderia cepacia and B.gladioli and their distribution in clinical and environmental strains of B. cepacia, J Appl Microbiol, 88, 914, 10.1046/j.1365-2672.2000.01033.x

Thông tin
Thông tin xuất bản

Journal of Medical Microbiology

Tập 52 Số 6

483-490

Thông tin tác giả